A research team led by a Medical University of South Carolina (MUSC) investigator reports in the May 6 issue of the New England Journal of Medicine that a four-month treatment regimen using rifapentine is effective for treating TB. Shortening the treatment duration is an important step toward increased patient adherence. Read here
top of page
Recent Posts
See AllA recent study on the incidence of MDR-TB in children and teens revealed that the prevalence has resurged. there was a 10 year drop from...
The Stop TB Partnership announced a major price reduction on bedaquiline. The cost per treatment course was slashed by over 50%,...
The shutdown and dismantling of USAID has had large ramifications for TB services. As one of the largest funding sources for TB, the...
bottom of page
Comments